As of January 3, 2023, Oyster Point Pharma, Inc. was acquired by Viatris Inc. Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.

Oyster Point Pharma, Inc.

Viatris is a global healthcare company that produces high-quality medicines across a range of therapeutic areas, including both noncommunicable and infectious diseases.

Viatris

Pharmaceutical Manufacturing

Oyster Point Pharma | 11,747 followers on LinkedIn. Commercial-stage biopharmaceutical company focused on pharmaceutical therapies to treat ophthalmic diseases. | Oyster Point Pharma is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases.

Kelly R.

	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21
account payables	418K -	462K 10.53%	500K 8.23%	2.28M 355.80%	6.50M 185.04%
accumulated other comprehensive income loss			-19K -
cash and cash equivalents	22.31M -	5.23M 76.57%	139.15M 2,561.57%	192.59M 38.40%	193.37M 0.41%
cash and short term investments	22.31M -	5.23M 76.57%	139.15M 2,561.57%	192.59M 38.40%	193.37M 0.41%
common stock	1K -	1K 0%	21K 2,000%	26K 23.81%	27K 3.85%
deferred revenue			-296K -	-418K 41.22%
deferred revenue non current
deferrred tax liabilities non current
goodwill
goodwill and intangible assets
intangible assets
inventory					6.09M -
long term debt			512K -	269K 47.46%	91.93M 34,075.84%
long term investments					886K -
net debt	-22.31M -	-5.17M 76.85%	-138.34M 2,577.87%	-191.90M 38.72%	-100.64M 47.55%
net receivables					6.66M -
other assets
other current assets	863K -	390K 54.81%	3.03M 677.69%	3.78M 24.70%	9.14M 141.57%
other current liabilities	1.65M -	478K 71.01%	4.90M 924.90%	8.70M 77.65%	21.51M 147.17%
other liabilities
other non current assets		20K -	51K 155%	61K 19.61%	1.08M 1,673.77%
other non current liabilities	43.00M -	43.01M 0.01%			2.35M -
othertotal stockholders equity	122K -	276K 126.23%	78.32M 28,276.09%	341.38M 335.89%	354.92M 3.97%
preferred stock			143.21M -
property plant equipment net		66K -	978K 1,381.82%	1.48M 51.53%	5.40M 264.30%
retained earnings	-22.02M -	-38.52M 74.96%	-84.23M 118.67%	-154.75M 83.72%	-255.41M 65.05%
short term debt			296K -	418K 41.22%	795K 90.19%
short term investments
tax assets
tax payables
total assets	23.17M -	5.70M 75.39%	143.21M 2,410.68%	197.91M 38.20%	222.62M 12.48%
total current assets	23.17M -	5.62M 75.76%	142.18M 2,430.79%	196.37M 38.11%	215.25M 9.62%
total current liabilities	2.07M -	940K 54.52%	5.40M 474.36%	10.98M 103.41%	28.80M 162.27%
total debt		62K -	808K 1,203.23%	687K 14.98%	92.73M 13,397.53%
total investments					886K -
total liabilities	45.07M -	43.95M 2.49%	5.91M 86.55%	11.25M 90.34%	123.08M 993.95%
total liabilities and stockholders equity	23.17M -	5.70M 75.39%	143.21M 2,410.68%	197.91M 38.20%	222.62M 12.48%
total non current assets		86K -	1.03M 1,096.51%	1.54M 49.95%	7.37M 377.45%
total non current liabilities	43.00M -	43.01M 0.01%	512K 98.81%	269K 47.46%	94.28M 34,947.58%
total stockholders equity	-21.89M -	-38.24M 74.67%	137.30M 459.01%	186.66M 35.95%	99.54M 46.67%

COM:OYSTERPOINTRX

Viatris

Last Close

11.17

30/12 21:00

Volume Today

2.09M

Avg: -

Preview